Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-06T02:02:33.626Z Has data issue: false hasContentIssue false

20 - Testis

Published online by Cambridge University Press:  23 December 2009

By
Jim Barber  and
John Staffurth
Edited by
Louise Hanna ,
Tom Crosby  and
Fergus Macbeth
Jim Barber
Affiliation:
Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
John Staffurth
Affiliation:
Clinical Senior Lecturer, Oncology, Consultant Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
Louise Hanna
Affiliation:
Velindre Hospital, Cardiff
Tom Crosby
Affiliation:
Velindre Hospital, Cardiff
Fergus Macbeth
Affiliation:
Velindre Hospital, Cardiff
Get access

Summary

Introduction

The treatment of testicular cancer is a success story for oncology, with high cure rates even for patients with advanced metastatic disease. The management has changed little over the past 20 years, there is a high degree of consensus about treatment, and standard protocols are well developed. Nonetheless, patients with testicular cancer are best managed by specialised multidisciplinary teams.

Range of cancers

The range of testicular cancers is shown in Table 20.1.

Germ cell tumours

Incidence and epidemiology

The annual incidence of germ cell tumours in the UK is approximately 800 cases. Germ cell tumours are the most common malignant tumours that occur in men between the ages of 25 and 35; there is a second peak between the ages of 55 to 65 years. The reason for the rapid rise in incidence in the Western world is not known. Theories range from the impact of environmental oestrogens, related to oral contraceptive use, to the increased scrotal temperatures resulting from the use of disposable diapers in infancy.

Risk factors and aetiology

Both genetic and epigenetic factors probably affect the development of testicular cancer. There is certainly a genetic component, with around 2% of cases reporting an affected first-degree relative, and a ten-fold increased relative risk in a brother of an affected relative. However, a range of conditions associated with subnormal testicular development, such as testicular maldescent, Klinefelter's syndrome, Down's syndrome and subfertility, are also associated with a higher risk of cancer.

Type
Chapter
Information
Practical Clinical Oncology , pp. 240 - 251
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bokemeyer, C. and Schmoll, H. J. (1995). Treatment of testicular cancer and the development of secondary malignancies. J. Clin. Oncol., 13, 283–92.CrossRefGoogle ScholarPubMed
Cullen, M. H., Stenning, S. P., Parkinson, M. C.et al. (1996). Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J. Clin. Oncol., 14, 1106–13.CrossRefGoogle Scholar
Wit, M., Hartmann, M., Brenner, W.et al. (2006). [18F]-fluorodeoxyglucose-positron emission tomography in germ cell tumors following chemotherapy: results of the German multicenter trial. J. Clin. Oncol., 24, (18 Suppl.), 4521.Google Scholar
Fossa, S. D., Ous, S., Lien, H. H.et al. (1989). Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J. Urol., 141, 557–9.CrossRefGoogle ScholarPubMed
Fossa, S. D., Horwich, A., Russell, J. M.et al. (1999). Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. J. Clin. Oncol., 17, 1146.CrossRefGoogle Scholar
Harland, S. J., Cook, P. A., Fossa, S. D.et al. (1998). Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. J. Urol., 160, 1353–7.CrossRefGoogle ScholarPubMed
Hendry, W. F., A'Hern, R. P., Hetherington, J. W.et al. (1993). Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit. Br. J. Urol., 71, 208–13.CrossRefGoogle ScholarPubMed
Horwich, A., Oliver, R. T., Wilkinson, P. M.et al. (2000). A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. Br. J. Cancer, 83, 1623–9.CrossRefGoogle ScholarPubMed
Huddart, R., O'Doherty, M., Padhani, A.et al. (2006). A prospective study of 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high risk clinical stage I (CS1) non-seminomatous germ cell cancer (non-seminomatous germ cell tumour): Medical Research Council study TE22. J. Clin. Oncol., 24, (18 Suppl.), 4520.Google Scholar
International Germ Cell Cancer Collaborative Group. (1997). International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J. Clin. Oncol., 15, 594–603.CrossRef
Lampe, H., Horwich, A., Norman, A.et al. (1997). Fertility after chemotherapy for testicular germ cell cancers. J. Clin. Oncol., 15, 239–45.CrossRefGoogle ScholarPubMed
Mead, G. M., Rustin, G. J., Stenning, S. P.et al. (2006). Medical Research Council trial of 2 versus 5 computed tomography scans in the surveillance of patients with stage I non-seminomatous germ cell tumours of the testis. J. Clin. Oncol., 24 (18 Suppl.), 4519.Google Scholar
Oliver, R. T., Mason, M., Mead, G. M.et al. (2005). Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet, 366, 293–300.CrossRefGoogle Scholar
O'Sullivan, J. M., Huddart, R. A., Norman, A. R.et al. (2003). Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann. Oncol., 14, 91–6.CrossRefGoogle ScholarPubMed
Patterson, H., Norman, A. R., Mitra, S. S.et al. (2001). Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother. Oncol., 59, 5–11.CrossRefGoogle ScholarPubMed
Shahidi, M., Norman, A. R., Dearnaley, D. P.et al. (2002). Late recurrences in 1263 men with testicular germ cell tumors. Multivariate analysis of risk factors and implications for management. Cancer, 95, 520–30.CrossRefGoogle ScholarPubMed
Maase, H. (2001). Do we have a new standard of treatment for patients with seminoma stage IIA and stage IIB?Radiother. Oncol., 59, 1–3.CrossRefGoogle ScholarPubMed
Williams, S. D., Birch, R., Einhorn, L. H.et al. (1987). Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med., 316, 1435–40.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Testis
    • By Jim Barber, Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK, John Staffurth, Clinical Senior Lecturer, Oncology, Consultant Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
  • Edited by Louise Hanna, Tom Crosby, Fergus Macbeth
  • Book: Practical Clinical Oncology
  • Online publication: 23 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545375.021
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Testis
    • By Jim Barber, Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK, John Staffurth, Clinical Senior Lecturer, Oncology, Consultant Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
  • Edited by Louise Hanna, Tom Crosby, Fergus Macbeth
  • Book: Practical Clinical Oncology
  • Online publication: 23 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545375.021
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Testis
    • By Jim Barber, Consultant, Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK, John Staffurth, Clinical Senior Lecturer, Oncology, Consultant Clinical Oncologist, Velindre Cancer Centre, Velindre Hospital, Whitchurch, Cardiff, UK
  • Edited by Louise Hanna, Tom Crosby, Fergus Macbeth
  • Book: Practical Clinical Oncology
  • Online publication: 23 December 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545375.021
Available formats
×